Next-generation sequencing-based characterization of the invasion by anatomical contiguity in a primary osseous diffuse large B-cell lymphoma. Correlation between the genetic profile of the malignancy and the clinical outcome of the patient

Histol Histopathol. 2019 Jun;34(6):663-670. doi: 10.14670/HH-18-067. Epub 2018 Nov 23.

Abstract

Primary bone lymphoma is now a well-described entity in the World Health Organization (WHO) Classification of Tumors of Soft Tissue and Bone as a malignancy of the lymphoid tissue, with at least one mass within bone, without involvement of supraregional lymph nodes or other extranodal sites. In the current paper, we describe the complete characterization of the mutational landscape of a diffuse large B cell non-Hodgkin's lymphoma (DLBLCL) of the tibial plateau. Currently, there is very little data about the genetic landscape of primary osseous lymphomas and about the genetic background of this type of malignancy, resistant to chemotherapy and invading the surrounding tissues. In the current paper, we describe the complete characterization of the mutational landscape of a DLBCL of the tibial plateau. Our data is consistent with already published data, that have shown that MKI67 activation is correlated with lymphoma progression. Along with a high Ki67 index, resistance to chemotherapy occurs with neurogenic locus notch homolog protein 1 (Notch) and KRAS activation. This is the first molecular characterization for the invasion by anatomical contiguity for a primary bone lymphoma and while we only characterized one case and further deep sequencing analyses are required, we can explain the clinical dismal evolution of the patient by correlating them with the genetic landscape of this type of lymphoma.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • DNA Mutational Analysis
  • Disease Progression
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Ki-67 Antigen / metabolism
  • Lymphoma, B-Cell / genetics*
  • Lymphoma, B-Cell / pathology*
  • Lymphoma, Large B-Cell, Diffuse / genetics*
  • Lymphoma, Large B-Cell, Diffuse / pathology*
  • Male
  • Mutation*
  • Neoplasm Invasiveness
  • Proto-Oncogene Proteins p21(ras) / metabolism
  • Receptor, Notch1 / metabolism
  • Treatment Outcome

Substances

  • KRAS protein, human
  • Ki-67 Antigen
  • NOTCH1 protein, human
  • Receptor, Notch1
  • Proto-Oncogene Proteins p21(ras)